Why do specialty drugmakers shell out on DTC? A few hits can pay off

Direct-to-consumer advertising may not seem like the most logical investment for companies trying to reach tiny, targeted patient populations. When drug prices are high enough, though? It's worth it for some drugmakers, and that's got them putting some of the industry's priciest treatments on display. More from FiercePharma

Suggested Articles

​​​​​​​Baseball and allergy season are in full swing, and Houston Astros pitcher Justin Verlander knows both. He stars in GSK's new seasonal push.

PhRMA’s latest round of drug-cost ads defends a drugmaker favorite—the copay coupon—against new payer programs designed to thwart it.

Researchers plan to tackle issues related to accelerated approval, risk comprehension for new drugs, scientific versus promotional claims and TV ads.